2022
DOI: 10.7759/cureus.21904
|View full text |Cite
|
Sign up to set email alerts
|

Salbutamol-Induced QT Interval Prolongation in a Two-Year-Old Patient

Abstract: Salbutamol-induced QT interval prolongation is a relatively rare adverse effect of beta2-agonists. We report a case of a two-year-old female patient with no known past medical history, brought by her parents to the ED 30 minutes after ingesting a total dose of 97 mg of salbutamol solution. ECG was done for the patient when she arrived and showed sinus tachycardia with prolonged QTc (509 ms) and normal QRS complex. The patient was admitted to the Pediatric Intensive Care Unit (PICU) with persistent tachycardia … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0
1

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 27 publications
0
1
0
1
Order By: Relevance
“…The syndrome of beta 2-agonist toxicity should be known to all doctors because it might result in QT prolongation and sudden cardiac death. 7 It is not recommended to administer systemic salbutamol via intravenous infusion to asthma patients beyond the clinical studies due to its metabolic effects, which could exacerbate respiratory function in asthma. Consideration should be made to other therapy such non-invasive ventilation for patients who don't respond to systemic steroids, ipratropium, or inhaled beta 2-agonists rather than increasing the dosage potency or amount of a medication that could paradoxically make respiratory function worse.…”
Section: Discussionmentioning
confidence: 99%
“…The syndrome of beta 2-agonist toxicity should be known to all doctors because it might result in QT prolongation and sudden cardiac death. 7 It is not recommended to administer systemic salbutamol via intravenous infusion to asthma patients beyond the clinical studies due to its metabolic effects, which could exacerbate respiratory function in asthma. Consideration should be made to other therapy such non-invasive ventilation for patients who don't respond to systemic steroids, ipratropium, or inhaled beta 2-agonists rather than increasing the dosage potency or amount of a medication that could paradoxically make respiratory function worse.…”
Section: Discussionmentioning
confidence: 99%
“…У них усиливаются симпатические реакции на β2-агонисты, что может способствовать повышению сердечно-сосудистого риска при БА[15]. M. Elgassim et al[16] описали индуцированное сальбутамолом удлинение интервала QT, что является относительно редким ПЭ β2агонистов. Специалисты сообщили о случае 2-летней пациентки, которую родители доставили в отделение неотложной помощи через 30 минут после приема общей дозы 97 мг раствора сальбутамола со стойкой тахикардией и тахипноэ.…”
unclassified